Business Context and Reporting Period
This Form 8-K is a current report filed by Akers Biosciences, Inc. (Ticker: AKER) on September 24, 2019. The company is incorporated in New Jersey and is designated as an emerging growth company. The filing addresses a procedural update regarding a pending securities class action lawsuit.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to legal proceedings and does not contain financial performance data.
Material Changes
The material change reported is the rescheduling of a hearing to determine the approval of a proposed class action settlement. The hearing was originally scheduled for November 8, 2019, and has been moved to December 20, 2019, at 11:00 A.M. New York Time. The hearing will be presided over by the Honorable Esther Salas in Newark, New Jersey.
Guidance, Outlook, and Risks
- Legal Contingency: The company is involved in a securities litigation concerning certain purchasers of its common stock. A settlement has been proposed, pending court approval.
- Management Commentary: The filing provides contact information for Lead Counsel (The Rosen Law Firm) and the Claims Administrator (Strategic Claims Services) for interested parties.
- Outlook: No financial guidance or operational outlook is provided in this document.
Key Facts for Investor Verification
- Verify the status of the class action settlement and the outcome of the rescheduled hearing on December 20, 2019.
- Confirm the potential financial impact of the settlement on the company's balance sheet.
- Review the specific allegations in the securities litigation to understand the underlying risks.
- Check for subsequent filings regarding the final court approval of the settlement.